VRDN-001 Market Summary
The VRDN-001 market is poised for substantial growth over the forecast period, underpinned by strong Phase III clinical results, a differentiated efficacy and safety profile, and an expanding addressable population in Thyroid Eye Disease (TED). VRDN-001 (veligrotug), developed by Viridian Therapeutics, achieved all primary and secondary endpoints in the pivotal THRIVE study in active TED, and subsequent THRIVE-2 data confirmed efficacy in chronic TED as well, meaningfully broadening the treatment-eligible population.
The therapy has been positioned as a potential best-in-class alternative to Amgen’s TEPEZZA, offering fewer infusions, lower overall drug exposure, and a favorable tolerability profile. In May 2025, the FDA granted Breakthrough Therapy Designation to veligrotug, supporting an accelerated regulatory pathway, with a BLA submission targeted for the second half of 2025 and potential US commercialization beginning in 2026. Analysts have estimated a commercial opportunity exceeding US$1 billion by 2030 for Viridian’s TED franchise, with some projections placing peak sales for veligrotug alone near US$2 billion.
Explore DelveInsight’s Full Coverage on the VRDN-001 Market
VRDN-001 Overview
VRDN-001 (veligrotug) is an investigational fully human monoclonal antibody developed by Viridian Therapeutics for the treatment of thyroid eye disease (TED), a rare autoimmune disorder associated with Graves’ disease. The therapy targets and antagonizes the insulin-like growth factor-1 receptor (IGF-1R), a clinically validated pathway involved in the inflammation, tissue remodeling, fibrosis, and proptosis characteristic of TED.
Designed as a differentiated alternative to existing IGF-1R therapies, VRDN-001 has demonstrated potent and complete receptor blockade in preclinical studies and encouraging efficacy in reducing proptosis, diplopia, and inflammatory symptoms across Phase I/II and Phase III trials in both active and chronic TED patients. Administered intravenously, the therapy has generally shown favorable tolerability and a potentially improved dosing profile relative to currently approved therapies. Viridian is also developing subcutaneous follow-on formulations, including elegrobart, to improve patient convenience and enable at-home administration.
Explore VRDN-001 market trends and future growth outlook
VRDN-001 Mechanism, Clinical Value, and Treatment Impact
VRDN-001 achieved a 70% proptosis responder rate at week 15 in the THRIVE study, with a placebo-adjusted response rate of 64% (p<0.0001). Additionally, 54% of patients achieved complete diplopia resolution, and 64% achieved a reduction in Clinical Activity Score (CAS) to 0 or 1. THRIVE-2 later confirmed efficacy in chronic TED, significantly expanding the addressable population beyond active disease alone.
Viridian has highlighted veligrotug’s ability to achieve strong efficacy with reduced overall drug burden, with hearing impairment adverse events occurring at a placebo-adjusted rate of only 5.5%, lower than historical concerns associated with TEPEZZA. Long-term follow-up data further showed that 70% of week-15 proptosis responders maintained their response through week 52, underscoring durability of response, an important consideration given the risk of relapse and persistent orbital changes in TED.
VRDN-001 Market Dynamics
The VRDN-001 market is being shaped by strong late-stage clinical performance, a differentiated positioning strategy, and a large, underserved patient population. TED remains significantly underdiagnosed and undertreated globally, and the commercial success of TEPEZZA has already validated the attractiveness of the TED market, with annual sales exceeding blockbuster levels.
VRDN-001’s potential best-in-class profile, fewer infusions, lower drug exposure, and improved tolerability compared with TEPEZZA, positions it to capture meaningful share as it approaches commercialization. Breakthrough Therapy Designation further supports an accelerated regulatory timeline via Priority Review eligibility. Viridian’s parallel development of subcutaneous follow-on candidates, including elegrobart, is expected to broaden the franchise’s long-term commercial opportunity by improving convenience and reducing reliance on intravenous infusion.
VRDN-001 Recent Developments
- In May 2026, Viridian Therapeutics announced positive topline data from the REVEAL 2 Phase III trial of elegrobart in patients with chronic thyroid eye disease. Elegrobart is a subcutaneously delivered, half-life-extended monoclonal antibody targeting IGF-1R. REVEAL 2 evaluated two dosing regimens, every four weeks (Q4W) and every eight weeks (Q8W), compared with placebo.
- This follows earlier milestones including FDA Breakthrough Therapy Designation for veligrotug in May 2025 and a planned BLA submission in the second half of 2025, with commercialization anticipated to begin in 2026 pending approval.
VRDN-001 Market Outlook
The VRDN-001 market outlook remains favorable through 2034, supported by strong Phase III efficacy, durability of response, and an expanding population encompassing both active and chronic TED. The therapy’s potential to offer a differentiated profile relative to TEPEZZA, combined with an accelerated regulatory pathway via Breakthrough Therapy Designation, positions it for a meaningful commercial launch.
The continued development of subcutaneous follow-on candidates such as elegrobart may represent an important next phase in the franchise’s lifecycle, offering improved convenience and supporting long-term growth. Analysts have estimated a US$1 billion+ opportunity by 2030 for Viridian’s TED franchise, with some projections placing peak sales for veligrotug alone near US$2 billion under favorable competitive positioning.
VRDN-001 Competitive Landscape
VRDN-001 enters a TED market currently led by TEPEZZA, the first and only approved therapy for the condition. However, VRDN-001’s differentiated profile, fewer infusions, lower drug exposure, and improved tolerability, positions it as a strong potential challenger. Other emerging products for Graves ophthalmopathy are also expected to intensify competition as additional late-stage therapies approach launch.
VRDN-001’s future market position will likely depend on its ability to demonstrate durable efficacy and safety advantages, secure timely regulatory approval, and capitalize on lifecycle strategies such as subcutaneous formulations. Pricing strategy, reimbursement support, and competitive intelligence will also be central to its commercial trajectory in the immunology landscape.
VRDN-001 Analytical Perspective by DelveInsight
The VRDN-001 market report provides a detailed assessment of VRDN-001 for potential indications such as Graves ophthalmopathy across the seven major markets, including the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan, for the study period 2020–2034. It offers a comprehensive view of current and forecasted VRDN-001 sales, along with product overview, mechanism of action, dosage and administration, regulatory milestones, research and development activities, SWOT analysis, competitive landscape, pricing and reimbursement analysis, and clinical differentiation versus existing therapies.
The report also includes a detailed clinical assessment of VRDN-001, covering trial interventions, trial conditions, trial status, and start and completion dates. In addition, it evaluates VRDN-001’s market potential, revenue forecast, competitive positioning, strengths and weaknesses relative to competitors, and broader strategic considerations that may influence its commercial trajectory in Graves ophthalmopathy and related indications.
Discover VRDN-001 market opportunities across the 7MM
Conclusion
The VRDN-001 market is poised for significant growth through 2034, driven by strong Phase III clinical results, a potential best-in-class profile, and an accelerated regulatory pathway supported by Breakthrough Therapy Designation. Having achieved all primary and secondary endpoints in THRIVE and confirmed efficacy in chronic TED through THRIVE-2, veligrotug has established a compelling clinical foundation ahead of anticipated commercialization in 2026.
Looking ahead, the VRDN-001 market is expected to benefit from multiple growth catalysts, including durable treatment response, a differentiated safety profile versus TEPEZZA, and the continued development of subcutaneous follow-on candidates such as elegrobart. While competition from TEPEZZA and other emerging therapies will remain significant, VRDN-001’s clinical differentiation and lifecycle strategy position it strongly for long-term growth in the TED treatment landscape.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact Us
Contact Person: Abhishek kumar
Email: info@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
